Assembly Biosciences Gets $30.1M Equity Investment, Funding From Gilead

Dow Jones12-19

By Chris Wack

Assembly Biosciences said it has received a $20.1 million equity investment from Gilead Sciences, along with $10 million in accelerated funding.

Gilead is buying the additional Assembly Bio stock, with an amendment to their collaboration with Assembly to advance the research and development of novel antiviral therapies.

With the new equity investment, Gilead increases its equity ownership of Assembly Bio to 29.9%.

Funding received from Gilead will support the advancement of Assembly Bio's clinical pipeline of antiviral therapeutic candidates for herpesviruses, hepatitis D virus and hepatitis B virus.

The amendment to the collaboration agreement adjusts the option timepoints and option payment structure for ABI-6250, an orally bioavailable viral entry inhibitor for the treatment of hepatitis D virus, to support updated clinical strategies to accelerate and optimize program development. As part of this amendment, $10 million of option-related payments for this program have been accelerated.

The accelerated funding amount reflects a portion of option-related payments that Assembly Bio is eligible to receive for ABI-6250 and will be creditable against future payments under the collaboration agreement. The scope of Gilead's option and Assembly Bio's right to opt in to share profits and costs in the U.S. are unchanged.

With the accelerated $10 million payment resulting from the collaboration amendment and the $20.1 million additional equity investment, Assembly Bio expects its cash runway to extend to mid-2026.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

December 19, 2024 08:23 ET (13:23 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2492512073?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-19 21:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492512073","market":"sg","top_or_hot":-1,"title":"Assembly Biosciences Gets $30.1M Equity Investment, Funding From Gilead","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre>\n \n</pre>\n<p>\n  Assembly Biosciences said it has received a $20.1 million equity investment from Gilead Sciences, along with $10 million in accelerated funding. \n</p>\n<p>\n  Gilead is buying the additional Assembly Bio stock, with an amendment to their collaboration with Assembly to advance the research and development of novel antiviral therapies. \n</p>\n<p>\n  With the new equity investment, Gilead increases its equity ownership of Assembly Bio to 29.9%. \n</p>\n<p>\n  Funding received from Gilead will support the advancement of Assembly Bio's clinical pipeline of antiviral therapeutic candidates for herpesviruses, hepatitis D virus and hepatitis B virus. \n</p>\n<p>\n  The amendment to the collaboration agreement adjusts the option timepoints and option payment structure for ABI-6250, an orally bioavailable viral entry inhibitor for the treatment of hepatitis D virus, to support updated clinical strategies to accelerate and optimize program development. As part of this amendment, $10 million of option-related payments for this program have been accelerated. \n</p>\n<p>\n  The accelerated funding amount reflects a portion of option-related payments that Assembly Bio is eligible to receive for ABI-6250 and will be creditable against future payments under the collaboration agreement. The scope of Gilead's option and Assembly Bio's right to opt in to share profits and costs in the U.S. are unchanged. \n</p>\n<p>\n  With the accelerated $10 million payment resulting from the collaboration amendment and the $20.1 million additional equity investment, Assembly Bio expects its cash runway to extend to mid-2026. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 19, 2024 08:23 ET (13:23 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Assembly Biosciences Gets $30.1M Equity Investment, Funding From Gilead</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAssembly Biosciences Gets $30.1M Equity Investment, Funding From Gilead\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-19 21:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Chris Wack \n\n\n \n\n\n  Assembly Biosciences said it has received a $20.1 million equity investment from Gilead Sciences, along with $10 million in accelerated funding. \n\n\n  Gilead is buying the ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0889565916.HKD","symbol_name":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2492512073","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492512073","pubTimestamp":1734614580,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Assembly Biosciences said it has received a $20.1 million equity investment from Gilead Sciences, along with $10 million in accelerated funding.Gilead is buying the additional Assembly Bio stock, with an amendment to their collaboration with Assembly to advance the research and development of novel antiviral therapies.With the new equity investment, Gilead increases its equity ownership of Assembly Bio to 29.9%.Funding received from Gilead will support the advancement of Assembly Bio's clinical pipeline of antiviral therapeutic candidates for herpesviruses, hepatitis D virus and hepatitis B virus.The amendment to the collaboration agreement adjusts the option timepoints and option payment structure for ABI-6250, an orally bioavailable viral entry inhibitor for the treatment of hepatitis D virus, to support updated clinical strategies to accelerate and optimize program development. As part of this amendment, $10 million of option-related payments for this program have been accelerated.T","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","ASMB":"Assembly Biosciences Inc.","BK4215":"住宅房地产投资信托","BK4532":"文艺复兴科技持仓","LU1839511570.USD":"WELLS FARGO GLOBAL FACTOR ENHANCED EQUITY \"I\" (USD) ACC","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4566":"资本集团","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD","BK4578":"CAR-T","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","BK4568":"美国抗疫概念","BK4588":"碎股","LU0058720904.USD":"联博国际健康护理基金A","BK4550":"红杉资本持仓","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1430594728.SGD":"Eastspring Investments - Global Low Volatility Equity AS SGD","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU2087621335.USD":"ALLSPRING GLOBAL FACTOR ENHANCED EQUITY \"A\" (USD) ACC","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","GILD":"吉利德科学","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0234570918.USD":"高盛全球核心股票组合Acc Close","EQR":"资产住宅公司","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","BK4583":"猴痘概念","IE00B7SZLL34.SGD":"Legg Mason ClearBridge - Value A Acc SGD-H"},"translate_title":"Assembly Biosciences获得吉利德3010万美元股权投资","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASMB":1,"EQR":1,"GILD":0.9},"content_text":"By Chris Wack \n\n\n \n\n\n  Assembly Biosciences said it has received a $20.1 million equity investment from Gilead Sciences, along with $10 million in accelerated funding. \n\n\n  Gilead is buying the additional Assembly Bio stock, with an amendment to their collaboration with Assembly to advance the research and development of novel antiviral therapies. \n\n\n  With the new equity investment, Gilead increases its equity ownership of Assembly Bio to 29.9%. \n\n\n  Funding received from Gilead will support the advancement of Assembly Bio's clinical pipeline of antiviral therapeutic candidates for herpesviruses, hepatitis D virus and hepatitis B virus. \n\n\n  The amendment to the collaboration agreement adjusts the option timepoints and option payment structure for ABI-6250, an orally bioavailable viral entry inhibitor for the treatment of hepatitis D virus, to support updated clinical strategies to accelerate and optimize program development. As part of this amendment, $10 million of option-related payments for this program have been accelerated. \n\n\n  The accelerated funding amount reflects a portion of option-related payments that Assembly Bio is eligible to receive for ABI-6250 and will be creditable against future payments under the collaboration agreement. The scope of Gilead's option and Assembly Bio's right to opt in to share profits and costs in the U.S. are unchanged. \n\n\n  With the accelerated $10 million payment resulting from the collaboration amendment and the $20.1 million additional equity investment, Assembly Bio expects its cash runway to extend to mid-2026. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 19, 2024 08:23 ET (13:23 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,corporation","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2492512073"}